A pegilált interferon-alfa-2a-és ribavirinkezelés hatékonysága krónikus C-vírus-hepatitises betegeken: Az elso hazai tapasztalatok egy multicentrikus, nyílt, prospektív vizsgálat alapján

Translated title of the contribution: Treatment of patients with chronic hepatitis C, using pegylated interferon alfa-2a and ribavirin - The first experiences in Hungary based upon a multicentric, open, prospective study

István Tornai, Lajos Dalmi, Judit Gervain, Gábor Horváth, István Nagy, Elemér Nemesánszky, Pál Ribiczey, László Telegdy, Tibor Várkonyi, Klára Werling

Research output: Contribution to journalArticle

7 Citations (Scopus)


INTRODUCTION - The treatment of patients with hepatitis C virus infection is one of the most challenging tasks in hepatology nowadays. PATIENTS AND METHODS - Between 2001 and 2004, during a phase III, prospective, multicentric, international open trial 69 patients (35 naive and 34 non-responder or relapser) with chronic hepatitis C were treated, using 180 μg pegylated interferon alfa-2a once weekly and 800-1200 mg daily ribavirin. The inclusion and exclusion criteria were the same as in the normal daily practice. Five patients were treated for 24 weeks and 54 were treated for 48 weeks. The treatment was stopped in 10 additional patients. Sustained virological response was the main end-point of the trial, after 24 weeks of follow-up. RESULTS - The mean age of the patients was 46 years. In all the patients virus genotype 1 could be detected. In none of the patients, treated for 24 weeks, sustained remission could be obtained. In patients, treated for 48 weeks, the overall sustained virological remission was 48%. The outcome of the treatment was better, if the patient was naive to the treatment, could receive the full dosage of drugs and had no liver cirrhosis. The best result could be obtained if the patient was naive to the therapy and younger than age 40. Viral load, however, did not show any effect on viral remission in our patients. At week 24, a negative HCV RNA had a positive predictive value of 68%, while a positive virus test had a negative predictive value of 93%, regarding sustained remission. CONCLUSION - Considering the high rate of genotype 1, pegylated interferon alfa-2a and ribavirin proved to be a very effective therapy in Hungarian chronic hepatitis C patients.

Original languageHungarian
Pages (from-to)807-813
Number of pages7
JournalLege Artis Medicinae
Issue number11
Publication statusPublished - Nov 2005


ASJC Scopus subject areas

  • Medicine(all)

Cite this